TrialEndocrine journal2026

Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial.

Kenji Ashida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.